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Infections caused by multidrug resistant (MDR) bacteria are a major public health threat. Carbapenems are
among themost potent antimicrobial agents that are commercially available to treat MDR bacteria. Bacterial
production of carbapenem-hydrolysing metallo-b-lactamases (MBLs) challenges their safety and efficacy,
with subclass B1 MBLs hydrolysing almost all b-lactam antibiotics. MBL inhibitors would fulfil an urgent
clinical need by prolonging the lifetime of these life-saving drugs. Here we report the synthesis and
activity of a series of 2-mercaptomethyl-thiazolidines (MMTZs), designed to replicate MBL interactions
with reaction intermediates or hydrolysis products. MMTZs are potent competitive inhibitors of B1 MBLs
in vitro (e.g., Ki ¼ 0.44 mM vs. NDM-1). Crystal structures of MMTZ complexes reveal similar binding
patterns to the most clinically important B1 MBLs (NDM-1, VIM-2 and IMP-1), contrasting with previously
studied thiol-based MBL inhibitors, such as bisthiazolidines (BTZs) or captopril stereoisomers, which
exhibit lower, more variable potencies and multiple binding modes. MMTZ binding involves thiol
coordination to the Zn(II) site and extensive hydrophobic interactions, burying the inhibitor more deeply
within the active site than D/L-captopril. Unexpectedly, MMTZ binding features a thioether–p interaction
with a conserved active-site aromatic residue, consistent with their equipotent inhibition and similar
binding to multiple MBLs. MMTZs penetrate multiple Enterobacterales, inhibit NDM-1 in situ, and restore
carbapenem potency against clinical isolates expressing B1 MBLs. Based on their inhibitory profile and
lack of eukaryotic cell toxicity, MMTZs represent a promising scaffold for MBL inhibitor development.
These results also suggest sulphur–p interactions can be exploited for general ligand design in medicinal
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Fig. 1 Chemical structure of the (A) penicillins, (B) carbapenem
anionic intermediate, (C) bisthiazolidine (BTZ), (D) MMTZ scaffold
herein designed, (E) L-captopril reported in ref. 30 and 31 as an MBL
inhibitor, (F) thiazolidine-2-4-dicarboxylic acid reported in ref. 32 as an
































































































b-Lactams are the most frequently prescribed antibiotics as they
are well tolerated, bioavailable and broadly active against
multiple Gram-positive and -negative bacteria.1,2 Despite their
unrivalled therapeutic efficacy, the increasing occurrence of
multidrug-resistant (MDR) bacteria in clinical environments
has become a major public health problem.3 This situation is
aggravated by growing numbers of susceptible, compromised
patients, including patients with COVID-19 for whom coin-
fections with antibiotic-resistant bacteria are frequently
reported.4,5
Carbapenems are highly potent anti-infective agents that are
oen used to treat MDR Gram-negative bacteria.6 Among Gram-
negative bacteria, the main mechanism of carbapenem resis-
tance is the expression of b-lactamases, enzymes that hydrolyse
the b-lactam ring, rendering these compounds inactive against
their targets.1,7,8 Presently, the most worrisome b-lactamases are
the metallo-b-lactamases (MBLs), Zn(II)-dependent enzymes
that display a broad substrate prole, being capable of inacti-
vating penicillins, cephalosporins and carbapenems.9–12
Furthermore, these enzymes are refractory to the action of all
currently available b-lactamase inhibitors, including
mechanism-based compounds such as clavulanic acid, tazo-
bactam and sulbactam, the diazabicyclooctane avibactam, and
the boronate vaborbactam.1,7 MBLs are becoming increasingly
widespread in clinically relevant Gram-negative pathogens
including diverse Enterobacterales species, Pseudomonas aeru-
ginosa and Acinetobacter spp., on which they confer carbapenem
resistance.13 Since carbapenem resistant Gram-negative
bacteria are usually also extensively drug resistant (XDR), the
World Health Organization (WHO) has assigned them the
“highest priority for antibacterial drug research and develop-
ment”.14 The worldwide dissemination of genes encoding for
MBLs, and the continuing emergence of new enzymes and
variants, is rapidly making them leading contributors to the
global antibiotic resistance crisis.
MBLs are classied into three subclasses, with the most
clinically relevant enzymes of subclass B1 active with two Zn(II)
ions bound to their active site.10,15 Although the metal coordi-
nation sphere is conserved in all B1 enzymes, little homology is
present between the active sites of different enzymes even
within this subclass. For example, the most important B1
enzymes (those of the IMP, VIM and NDM families) share
approximately 30% sequence identity.9,10,16 This structural
diversity makes the development of a universal MBL inhibitor
an exceptionally challenging task.17–19 As a result, the use of
chelating compounds as MBL inhibitors has been pursued,20,21
despite the risk of off-target activity arising from indiscriminate
chelation of metal ions.
One strategy to address the challenge of MBL inhibition is to
exploit our current knowledge regarding common features of b-
lactam antibiotic binding and hydrolysis that are shared by
different MBLs despite their structural differences.19,22 Based on
this approach, we recently reported a series of bisthiazolidines
(BTZs), bicyclic substrate mimics decorated with a zinc-bindingChem. Sci.thiol moiety (Fig. 1), that are cross-class MBL inhibitors active in
vitro and against bacterial pathogens expressing MBLs.23–25 X-
ray crystallographic analyses of MBL:BTZ complexes revealed
that this scaffold mimics the structure of bicyclic substrates,
and that different stereochemistries can elicit different coordi-
nation modes within the active site, that nevertheless result in
equally effective inhibition.25
Common mechanistic features of MBLs are identied by
kinetic, spectroscopic and structural studies. MBLs of multiple
subtypes have been shown to hydrolyse carbapenems via
a common catalytic intermediate, in which the b-lactam ring
has already been cleaved, that interacts with the metal site in
a manner that is consistent across different enzyme targets.19,22
The binding mode of these intermediates resembles that re-
ported for several enzyme-product adducts described by X-ray
crystallography.7,26 Capturing features of the interactions of
hydrolytic intermediates, and related hydrolysed products, with
MBLs, can therefore guide the design of compounds aimed at
inhibiting multiple MBL targets.
Based on this knowledge, we here report a novel 2-
mercaptomethyl-thiazolidine (MMTZ) scaffold, a prototype that
partially resembles MBL-bound intermediates and product
species, whilst retaining the metal-binding thiol group present
in the BTZs. This “second advanced” series of inhibitors
displays more potent inhibitory activity than the earlier, “rst
generation” BTZs and can restore the activity of imipenem
against MBL-producing carbapenem resistant Enterobacterales
(MBL-CREs). Importantly, 2-mercaptomethyl-thiazolidinesMBL inhibitor.
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 2 (A) Synthetic scheme of 2-mercaptomethyl-thiazolidines
(MMTZs) and reaction yields. (B) Chemical structure of the MMTZ
inhibitors: L-anti-1a (brown), D-anti-1a (orange), L-anti-1b (green), L-
syn-1b (light blue), D-anti-1b (purple) and D-syn-1b (pink). The ster-
eocentres of the thiazolidine ring are labelled according to their
absolute configuration as S or R.































































































View Article Online(MMTZs) represent a synthetically accessible series of phar-
macophores that can be easily prepared by a condensation
reaction of aminothiols with mercapto-carbonyl compounds
masked under a dithiane form. All synthesised and tested
MMTZs show similar inhibitory potency against different B1
MBLs, consistent with a conserved mode of binding. MMTZ
stereoisomers display a less variable range of potencies than
stereoisomers of a chemically related compound, D/L-captopril,
a clinically approved anti-hypertensive agent previously inves-
tigated27 as an MBL inhibitor.28,29 Crystal structures of NDM-1,
VIM-2 and IMP-1 complexed with MMTZs reveal that this is
likely due to the reduced conformational exibility of MMTZs,
compared to the captopril series, and to the presence of
a conserved interaction between the sulphur atom of the thia-
zolidine (TZ) ring and an aromatic residue present at the base of
a mobile active site loop present in the different B1 enzymes.
Thus, MMTZs represent a novel scaffold able to inhibit the
clinically relevant B1 MBLs in vitro and in situ through
a conserved binding mode and constitute a promising new
avenue in the continuing search for MBL inhibitors.
Results
Design and synthesis of MMTZs
BTZs are bicyclic MBL inhibitors, designed as substrate mimics,
decorated with two zinc binding groups: a thiol and a carbox-
ylate (Fig. 1).23 Based on these features we envisioned that
a simpler, monocyclic compound, mimicking the reaction
intermediate or hydrolysis product, could allow us to better
explore stereochemical preferences in the in theMBL active site,
retaining themain binding features of the BTZs, but beingmore
versatile with respect to stereochemistry. In this regard, L-
captopril captures these features (Fig. 1), partially mimicking
the ve-membered ring present in hydrolysed penicillins and
conserving the carboxylate moiety, with the thiol group
providing an anchoring point to the metal binding site.29
However, different captopril stereoisomers demonstrate a range
of inhibitory potencies towards B1 MBLs.30,31 We reasoned that
a TZ scaffold bearing a thiol group and carboxylate moiety
(Fig. 1) could outperform or improve upon captopril due to the
shorter thiol-bearing side chain, that would restrict conforma-
tional mobility within the active site and provide a more rigid
metal-binding scaffold. Since a TZ containing two carboxylate
groups was shown to be a potent inhibitor of the B1 enzyme
CcrA (Fig. 1),32 we hypothesised that a MMTZ molecule would
elicit even more potent inhibition due to the presence of the
zinc-binding thiol moiety.
Thiazolidines are versatile motifs broadly used in medicinal
chemistry33 that can be easily obtained by the condensation
between carbonyls and 1,2-aminothiols. Based on the required
structural features, two series of 2-ethoxycarbonyl-2-
mercaptomethyl thiazolidine-4-carboxylic acids were designed
(Fig. 2), 1a with R ¼ H, and 1b with R ¼ Me, thus including the
gem dimethyl group present in penicillins. For each series, we
prepared the L and D enantiomers starting from the corre-
sponding L and D amino acids 2. The mercapto-ketone needed
for its preparation was used under the dithiane form 3, and© 2021 The Author(s). Published by the Royal Society of Chemistrysynthesised as previously reported.34 MMTZs were next
prepared by cyclocondensation of 1,2-aminothiols 2 and
dithiane 3 (Fig. 2), affording the syn/anti diastereomeric
mixtures, that were easily puried and evaluated as pure
compounds. In the case of MMTZ 1a, only the anti diastereomer
could be isolated, although both isomers were observed in NMR
spectra of the crude reaction. The two diastereomers of thia-
zolidine 1b were isolated and characterised independently.
MMTZs (L-anti-1a, D-anti-1a, L-anti-1b, D-anti-1b, L-syn-1b, D-syn-
1b) were prepared and isolated (Fig. 2). The stability of the
compound D-anti-1b was assessed in PBS (pH 7.2, 27 C). We
observed that, under these conditions, 88% of intact MMTZ
remains aer 6 hours (Fig. S1†). Analysis by LCMS indicates that
the MMTZ did not hydrolyse to penicillamine and the main
degradation product was the disulphide derivative (Fig. S2†).
MMTZs are potent MBL inhibitors
We assessed the inhibitory potency of the synthesised MMTZs
against three representatives, clinically important, subclass B1
MBLs: NDM-1, IMP-1, and VIM-2.17 Hydrolysis rates for the
carbapenem imipenem were determined under steady-state
conditions in the presence of MMTZs, with progress curvesChem. Sci.
Table 1 Inhibition potencies of MBLs inhibitors. Ki of MMTZs and BTZs and IC50 of captopril compounds
Inhibition potency (mM)
Inhibitor Chemical structure NDM-1 IMP-1 VIM-2 Ref.
L-anti-1a 5.2  0.7 1.0  0.2 0.38  0.05 This work
D-anti-1a 2.5  0.5 1.3  0.1 0.39  0.04 This work
L-anti-1b 0.44  0.06 0.46  0.05 0.75  0.09 This work
L-syn-1b 8  1 6.0  0.6 3.6  0.4 This work
D-anti-1b 3.1  0.3 0.93  0.08 0.9  0.1 This work
D-syn-1b 0.60  0.05 2.0  0.2 1.9  0.1 This work
L-BTZ-1 7  1 8  2 2.9  0.4 23 and 25
D-BTZ-1 19  3 6  1 3.2  0.4 23 and 25
L-BTZ-2 18  3 15  3 6  1 23 and 25
D-BTZ-2 12  1 14  3 10  2 23 and 25
L-Captopril 157  1 23  1 4.4  0.8 31
D-Captopril 20  2 7  1 0.07  0.01 31
L-epi-Captopril >500 436  1 6  2 31
D-epi-Captopril 65  1 173  1 5.5  0.7 31































































































View Article Onlineable to be tted to a competitive inhibition model (Fig. S3 and
S4†) yielding inhibition constants (Ki) in the low-to sub-mM
range (Table 1).
All MMTZs were potent inhibitors of all three assayed MBLs,
with Ki values ranging between 0.38 and 8 mM. The two anti-Chem. Sci.enantiomers of MMTZ 1a showed similar potencies against
each enzyme (e.g. 5.2 and 2.5 mM against NDM-1 for L-anti-1a
and D-anti-1a, respectively) despite their differing enantiomeric
congurations. In contrast, for the MMTZs 1b, bearing a gem-
dimethyl group, the stereochemistry has an impact (though© 2021 The Author(s). Published by the Royal Society of Chemistry































































































View Article Onlinemodest) upon inhibition. In the case of NDM-1, Ki values for
these four compounds varied between 0.44 and 8 mM. Of the six
compounds tested, the two most potent NDM-1 inhibitors are L-
anti-1b (0.44 mM) and D-syn-1b (0.60 mM), both with the gem-
dimethyl group. Within the series of compounds 1b, the
heterocycles with the mercaptomethyl group in the 2S cong-
uration (L-anti-1b and D-syn-1b) were better inhibitors than
those in the 2R conguration: MMTZ L-anti-1b was 7-fold more
active against NDM-1 than its enantiomer D-anti-1b; and D-syn-
1b was 13 times more active than the enantiomer L-syn-1b. The
potencies displayed by MMTZs with an R stereocentre were
comparable to the Ki values of compounds from the 1a series.
The MMTZ inhibitors performed best against VIM-2 (Ki
values between 0.38 and 3.6 mM), with the two 1a compounds
showing the highest potency. For IMP-1, Ki values ranged
between 0.46 and 6 mM. Among compounds containing the gem-
dimethyl group (series 1b), MMTZs with an anti conguration
showed generally lower Ki values than their syn counterparts for
both VIM-2 and IMP-1. MMTZ L-anti-1b showed the best inhi-
bition prole against all three MBLs. Overall, the inhibitory
activity against MBLs is clearly better than that of BTZs against
the B1 enzymes (Table 1). In the case of NDM-1, L-anti-1b and D-
syn-1b are 12-fold more potent inhibitors than L-BTZ-1 (the best
compound within the BTZ series), with all other MMTZs dis-
playing equal lower or lower Ki values to those measured for L-
BTZ-1 (Table 1).
We then assessed the ability of these compounds to pene-
trate the bacterial outer membrane and inhibit NDM-1 within
the bacterial periplasm.35 To this end, we used 1HNMR to follow
imipenem hydrolysis by E. coli cells expressing NDM-1 in the
presence of the different inhibitors (Fig. S5†). NDM-1 in the E.
coli periplasm hydrolyses a solution of 500 mM imipenem
completely in 12–15 min (Fig. S5†). All MMTZs were able to
protect imipenem from the hydrolytic activity of NDM-1. Table 2
summarises the in-cell IC50 values for E. coli cells expressing
NDM-1. In E. coli, D-syn-1b was the most potent inhibitor (in-cell
IC50¼ 10 mM, Fig. S5 and S6†). MMTZs lacking the gem dimethyl
group, L-anti-1a and D-anti-1a, were 5 and 6 times less potent
than D-syn-1b. However, MMTZs bearing the gem dimethyl
group and different stereochemistry than D-syn-1b displayed
lower potencies. These relatively elevated IC50 values likely arise
from differences in cell penetration and in the stability of the
inhibitor thiol in the cellular environment. In comparison, L-
BTZ-1, displayed an in-cell IC50 for NDM-1-catalysed imipenemTable 2 In-cell IC50. Imipenem hydrolysis by E. coli cells expressing
NDM-1 was followed in the presence of different concentration of the
MMTZs
Inhibitor In-cell IC50 (mM)
L-anti-1a 54  4
D-anti-1a 64  5
L-anti-1b 160  10
L-syn-1b 230  30
D-anti-1b 210  10
D-syn-1b 10  1
© 2021 The Author(s). Published by the Royal Society of Chemistryhydrolysis of 23 mM,23 in the equivalent lowmicromolar range to
the value for D-syn-1b.MMTZs adopt a uniform binding mode to class B1 MBLs
To understand the interactions of MMTZs with the different B1
MBLs, we obtained the crystal structures of NDM-1, VIM-2 and
IMP-1 in complex with both L-anti-1b and D-syn-1b (resolutions
1.4–1.87 A, Table S1†), the most potent compounds in the
inhibition studies. In all cases clear positive Fo  Fc difference
density was observed in electron density maps derived from
inhibitor-exposed crystals. Compounds could be modelled into
these features (Fig. S7†) with real space correlation coefficients
(RSCC values, calculated during PDB submission) $0.91 (Table
S2†) giving high condence in the presence and correct tting
of bound inhibitor.36,37 For all enzymes inhibitors were
modelled into all molecules of the asymmetric unit (ASU), with
the exception of NDM-1:L-anti-1b, in which the inhibitor was
modelled in only one of the two chains in the ASU. Evidence of
inhibitor dimerization in the active sites was not present.
In all cases, the thiol moiety of the inhibitors binds equi-
distant between the two zinc ions, displacing the hydrolytic
water/hydroxide (Fig. 3 and Table S3†), and maintaining a Zn–
Zn distance of 3.57–3.79 A (Table S3†). This distance is consis-
tent with that reported for the uncomplexed forms of MBLs and
for some complexes with products and inhibitors.25,30,38–40
Additionally, several hydrophobic residues lining the active site
signicantly stabilise inhibitor binding. These include residues
on the mobile L3 loop, with NDM-1 Leu59, Met61 and Val67
contributing to binding in both inhibitor complexes (Fig. 3A
and B), while in VIM-2 Phe61 and Tyr67 at the base of the L3
loop are in close proximity to both inhibitors (Fig. 3C and D). In
IMP-1, due to a small conformational change in the exible L3
loop,25 either two (Val61, Phe87, L-anti-1b, Fig. 3E) or three
(Val61, Trp64, Phe87, D-syn-1b, Fig. 3F) hydrophobic residues
stabilise binding. Furthermore, the residue Trp87 (in NDM-1
and VIM-2) or Phe87 (IMP-1) is positioned close (approxi-
mately 4 A) from the ethoxy sidechain in all the MBL:MMTZ
complexes, providing a strong hydrophobic interaction. In
NDM-1 only, an additional hydrophobic residue, Ile29 situated
close to the N-terminus, also contributes to binding.
The inhibitors form few hydrogen bonds within the active
site (Table S3†). For L-anti-1b, the carboxylate interacts weakly
with Asn233 on the L10 loop in NDM-1 and IMP-1 (3.46 and 3.28
A, respectively), but this is not observed in the VIM-2 complex.
In complexes with D-syn-1b the inhibitor interacts more closely
with the backbone amide of Asn233 (2.56–3.07 A, Table S3†),
while in VIM-2 there is an additional weak interaction with
Arg228 (3.39 A) that is not present in NDM-1 and IMP-1.
Overlays of complexes of L-anti-1b with NDM-1, VIM-2 and
IMP-1 highlight the similarities in binding (Fig. S8A†), partic-
ularly between NDM-1 and IMP-1, with differences in the posi-
tioning of the L10 loop in VIM-2 resulting in a slightly different
orientation for the bound inhibitor. The structures also high-
light some exibility of binding for the ethoxy carbonyl side
chain, which is rotated 180 about the carbonyl carbon in the
IMP-1:L-anti-1b structure compared to NDM-1 or VIM-2, largelyChem. Sci.
Fig. 3 Interactions of MMTZs in the active sites of B1 MBLs. Crystal structures for complexes of L-anti-1b (green) with NDM-1 (A), VIM-2 (B) and
IMP-1 (C); and for complexes of D-syn-1b (pink) with NDM-1 (D), VIM-2 (E) and IMP-1 (F). Zinc ions are shown as grey spheres, blue side chains
denote hydrophobic residues involved in inhibitor interactions, thick sticks denote residues involved in hydrogen bonding interactions with
inhibitor, hydrogen bonding andmetal-coordinating interactions are shown as yellow dashed lines. Zinc-coordinating residues are shown as thin
sticks.































































































View Article Onlinedue to the lack of hydrogen bonds between the inhibitor side
chain and the protein backbone. This exibility is also apparent
in the electron density, which is more poorly dened for the
ethoxy –CH3 atoms in the NDM-1 structures (Fig. S7†).
The inhibitor D-syn-1b binds very similarly to NDM-1 and
IMP-1 (Fig. S8B†) but has a slightly different orientation in VIM-
2 due to interactions of the carboxylate with Arg228. Despite
these small differences in binding, however, both L-anti-1b and
D-syn-1b display broadly consistent binding modes, making few
(and weak) interactions with the protein backbone and with the
thiol:zinc interaction dominating binding.Role of a common S–p interaction on MMTZ binding
Notably, the sulphur atom of the thiazolidine ring of MMTZs is
located at 3.8 A from the edge of the indole group of NDM-1
Trp87, at the base of loop L3 (Fig. 4). A similar sulphur–p
interaction with an aromatic group at this position (Trp in
NDM-1 and VIM-2, Phe in IMP-1) is observed in all 6 complex
structures with the twoMMTZs (Fig. 4 and Table S3†). In NDM-1Chem. Sci.and IMP-1, the sulphur atom is located in a coplanar manner to
the edge of the aromatic ring, while in VIM-2, the sulphur forms
a stacking interaction with Trp87. The conservation of this
interaction does not seem to be incidental. Unfortunately,
attempts to test its role by preparing oxazolidine analogs, using
the same synthetic methodology, were unsuccessful (data not
shown). Therefore, we decided to explore its role in silico. Based
on the crystal structures of NDM-1 bound to L-anti-1b and D-syn-
1b, we constructed structural models of the analogous 2-mer-
captomethyl oxazolidines (MMOZs) bound to NDM-1 by
replacing the sulphur atom of the thiazolidine ring with an
oxygen atom. The experimental geometries of the bound
MMTZs and the simulated geometries of the bound MMOZs
were minimised by hybrid quantum mechanics molecular
calculations (QM/MM). The adducts of MMTZs with NDM-1
yielded nal geometries similar to those in the crystal struc-
ture, i.e., preserving the S–p distances (Fig. S9A and B†).
Instead, in the theoretical complexes with MMOZs, the inter-
action distance between the O atom and Trp87 was increased
upon geometry optimization (Fig. S9C and D†). The difference is© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 4 Interactions of the thiazolidine ring sulphur atom with the
aromatic group of the residue at position 87. Interactions (black
dashes) between the benzene ring of Trp87 or Phe87 (blue sticks) and
the thiazolidine sulphur of L-anti-1b (top, green sticks) or D-syn-1b
(bottom, pink sticks) in the active sites of NDM-1 (A and B), VIM-2 (C
and D) and IMP-1 (E and F). Distances shown in A are measured from
the centre of the benzene ring to the thiazolidine sulphur atom.































































































View Article Onlinemost prominent in the NDM-1:L-anti-1b complex which showed
an increase of 1.10 A when the O is present and signicant
movement of the ligand. In the NDM-1:D-syn-1b adduct, the O–p
distance is 0.34 A longer than the S–p distance. We conclude
that the presence of the thioether S favours the interaction with
the aromatic groups in all studied MBLs, contributing to
binding.MMTZs restore the action of imipenem against
Enterobacterales and are not toxic against eukaryotic cells
We analysed the activity of MMTZs against clinical isolates





K. pneumoniae (1.37) NDM 32 8
E. coli (8.68) NDM-1 64 16
K. pneumoniae (LC 82) IMP-13 1 0.5
Enterobacter spp. (42713) IMP 16 16
P. mirabilis (UNC KPC 170)a IMP 16 8
K. pneumoniae (6907) VIM-2 4 2
K. aerogenes (6915) VIM-2 8 4
K. pneumoniae (5639) VIM-24 8 8
a Due to intrinsic reduced susceptibility to imipenem, strains from the M
© 2021 The Author(s). Published by the Royal Society of Chemistryinhibitory concentration (MICs) of imipenem (Table 3). MMTZs,
particularly compound D-anti-1b, were able to successfully
inhibit the MBLs present in Enterobacterales, as evident by
a reduction of up to 16-fold in MIC values. In the absence of the
carbapenem antibiotic, none of the MMTZs inhibitors has
a detrimental effect on the bacterial growth, indicating that
reduction of the MIC values is due to the restoration of
susceptibility to imipenem through inhibition of the MBLs by
the MMTZ inhibitors.
Finally, we evaluated the cytotoxicity of the six MMTZs
against cultured HEK293, L929 and VERO cell lines at 260, 355
and 530 mM (Fig. 5). Encouragingly, compounds bearing the
gem dimethyl group did not show any toxicity under the assayed
conditions. However, MMTZ D-anti-1a induced a decline in cell
viability percentages in almost all conditions, while L-anti-1a
was more selectively toxic towards the HEK293 cell line. Overall,
however, the combined impact of MMTZs in lowering the MICs
of MBL-CRE, and their lack of or low toxicity, make them
promising compounds for development as MBL inhibitors.
Discussion
Here we report a series of MMTZs as potent inhibitors of B1
MBLs. These compounds showed comparable potencies against
the three representative MBLs enzymes (NDM-1, VIM-2 and
IMP-1, the most clinically important resistance determinants).
MMTZs were able to enter the periplasm of E. coli, as evidenced
by inhibition of NDM-1 catalysed imipenem hydrolysis in situ,
and restore the antimicrobial effect of imipenem against clin-
ical Enterobacterales. The discrepancies between the Ki and in-
cell IC50 values can be attributed either to the stability of the
thiol groups in the different strains or to differences in
permeability between the clinical strains. Despite differences in
the stereochemistry of individual inhibitors, the MMTZ scaffold
utilises a similar binding mode to bind to the active site of the
different MBLs tested.
As previously reported for most thiolate MBL inhibitors,25,30
the driving force for MMTZ binding to the active site is the
interaction with the metal centre of the thiolate, that bridges
the two Zn(II) ions and replaces the hydroxide/water nucleo-
phile. MMTZs share this binding mode with the related BTZs
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organellaceae family were tested using meropenem.
Chem. Sci.
Fig. 5 Cytotoxicity for the MMTZs in HEK293, L929 and VERO cell lines. Control (black), L-anti-1a (brown), D-anti-1a (orange), L-anti-1b (green),
L-syn-1b (light blue), D-anti-1b (purple), and D-syn-1b (pink).































































































View Article Onlinediffer from these compound classes through the absence of
electrostatic interactions, such as those of the carboxylate
groups of BTZs or captopril stereoisomers with Asn233
(conserved in most B1 MBLs) and Lys224 (NDM-1 and IMP-1) or
Arg228 (VIM-2) (Fig. S10 and S11†). These interactions have
been also identied as critical for substrate recognition by
MBLs. Notwithstanding, MMTZs show better inhibition poten-
cies against the B1 MBLs tested than BTZs or captopril stereo-
isomers. Most importantly, our data reveal that the different
MMTZs adopt a similar, common binding mode to their
different B1 MBL targets, contrasting with other thiol-based
inhibitors where binding is both enzyme and stereospecic.25,30
MMTZs were designed to mimic product-like reaction
intermediates (Fig. 1) or replicate enzyme:product interactions,
with the addition of a thiol to strengthen binding to the bi-Zn(II)
site. Therefore, we compared the bindingmodes of MMTZs with
some reported enzyme:product complexes, such as those of
NDM-1 with hydrolysed meropenem (PDB 5ypm41), cefuroxime
(PDB 5o2e42) and ampicillin (PDB 5zgr39). The ve-membered
rings of the MMTZs lies perpendicular in the active site with
respect to the rings of the hydrolysed antibiotics (Fig. S12†) as
a result of the electrostatic interactions of the b-lactam
carboxylate group with Lys224 that are not replicated by
MMTZs.
The conserved sulphur–p interaction (Fig. 4) plays a signi-
cant role in enhancing MMTZ binding, as conrmed by QM/
MM calculations. This interaction is not present in the
enzyme–product complexes of penicillins with MBLs,43 since
the thiazolidine ring of ampicillin is perpendicular to the
MMTZ thiazolidine ring (Fig. S12†). Therefore, MMTZs provide
stronger sulphur–aromatic interactions than penicillins
hydrolysis products.
In the case of the complex with the cephalosporin cefurox-
ime, the six-membered dihydrothiazine ring lies perpendicular
to the ve-membered ring of MMTZs. However, the geometry of
the cefuroxime dihydrothiazine ring enables the interaction of
the sulphur with Trp87 to be maintained (Fig. S12†). It is also
notable that, in MMTZ complexes with NDM-1, the position of
the L3 loop more closely resembles that observed in the
complex with hydrolysed meropenem than in those with either
ampicillin or cefuroxime. This may reect the absence in
MMTZs of a group equivalent to the relatively bulky C6/C7Chem. Sci.substituents of these substrates (as opposed to the much
smaller C6 hydroxyethyl group of meropenem), and the conse-
quent avoidance of possible steric clashes.
MMTZs also resemble the captopril stereoisomers (Table 1),
since both families of compounds have a carboxylate group
bound to a ve-membered ring (mimicking the intermediate/
product of penicillin hydrolysis) and an additional thiol
moiety. However, the different captopril stereoisomers exhibit
a wide range of inhibitory potencies towards B1 MBLs (Table 1).
For example, epi-D- and epi-L-captopril are only efficient inhibi-
tors of VIM-2, while showing greatly reduced potency against
NDM-1 and IMP-1.30 The adducts of D- and L-captopril with B1
MBLs show a similar binding mode in the active site, but the
D isomer is much more potent and targets a wider range of
MBLs. This is not the case for the different stereoisomers of the
MMTZs reported here, whose potencies across the range of
targets fall consistently within the low- to sub-mM range.
Selectivity of captopril D isomers has been explained by appre-
ciating the more extensive electrostatic interactions of the
carboxylate moiety with Lys224 (NDM-1, IMP-1) or Arg228 (VIM-
2) (Fig. S10†).30 A comparison of the binding modes of the
MMTZs with captopril reveals that the ve-membered ring of
MMTZs is positioned more deeply within the active site (i.e.
closer to the metal centre), despite the smaller number of
electrostatic interactions and hydrogen bonds formed by
MMTZs (Fig. S10†). This nding conrms our prediction that
a shorter side chain connecting the thiol group with the ve-
membered ring could enhance binding with respect to the
captopril variants.
We conclude that the consistent involvement in binding of
sulphur–p interactions (not possible for the pyrrolidine ring of
captopril) explains the better and more uniform inhibitory
potency of MMTZs against the range of B1 MBLs, compared to
the more variable potency of the different captopril isomers.
Similarly, although the related, but less potent, BTZs show
more consistent inhibitory potency across different MBL
targets, they do so by means of different binding modes that,
while overall conserving the electrostatic interactions of the
carboxylate group with residues at positions 224, 228 and 233,
vary markedly between MBL target and BTZ stereoisomer. Due
to their rigid bicyclic scaffold, none of the BTZs tested can adopt
a mode of binding that shows signicant sulphur–p© 2021 The Author(s). Published by the Royal Society of Chemistry































































































View Article Onlineinteractions, supporting our hypothesis that such an interac-
tion both enhances inhibitory potency and controls the
conformation in the MBL active site of bound MMTZ.
Thioether–aromatic interactions can stabilise ligand binding
by up to ca. 3.2 kcal mol1, an energy comparable to a salt
bridge, with the further advantage of being insensitive to pH
changes.44–46 The distances and orientations observed in these
MBL:MMTZ complexes (Fig. 4) are, based on previous experi-
mental and theoretical studies, expected to maximise these
interactions.46 This interaction orients the ve-membered ring
of the MMTZ within the active site, overriding the steering effect
of the electrostatic interactions that may be formed by the
carboxylate group. We conclude that the MMTZ scaffold
improves the affinity of the thiol binding group by favouring
hydrophobic contacts with the active site of B1 MBLs, speci-
cally by means of a sulphur–p interaction with the conserved
aromatic residue at position 87.
Conclusions
MMTZs were iteratively designed as a novel chemical scaffold to
inhibit B1 MBLs. The six puried inhibitors displayed inhibition
constants in the low- to sub-mM range for the B1 enzymes, with D-
syn-1b as overall the most consistently potent inhibitor of both the
different puried enzymes in vitro and, in combination with car-
bapenem antibiotics, in antibacterial assays against MBL-
expressing strains of clinical microorganisms such as E. coli.
These compounds are versatile and can be easily prepared with
high yields. Since we report that the carboxylate group of MMTZs is
not involved in signicant electrostatic interactions, the possibility
of introducing other substituents at the 4-position could result in
even more potent inhibitors to improve the development of this
scaffold. Furthermore, our discovery that the sulphur–p interaction
apparently plays a key role in inhibitor binding strongly supports
the suggestion that this feature can be exploited as a general
concept both inMBL inhibition, taking advantage of the availability
of conserved hydrophobic residues in accessible positions across




Reactions were monitored by analytical thin layer chromatog-
raphy (TLC) on 0.25 mm silica gel coated plastic sheets (SIL G/
UV 254). Flash chromatography on silica gel 60 (40 mm average
particle diameter) was used to purify the crude reaction
mixtures. All NMR spectra were recorded in CDCl3, at 300 K on
a Bruker Avance 400 MHz spectrometer equipped with a 5 mm
QXI probe and on an Avance III 400 MHz spectrometer equip-
ped with a 5 mm BBO probe. Chemical shis (d) are expressed
in ppm using tetramethylsilane (TMS) as internal reference, and
multiplicities are indicated as s (singlet), d (doublet), t (triplet),
q (quartet), m (multiplet), br (broad). All reactions were carried
out in dry, freshly distilled solvents under anhydrous conditions
unless otherwise stated. HRMS-ESI spectra were recorded on
MicroTOF-QTM (Bruker Daltonics) mass spectrometers. Optical© 2021 The Author(s). Published by the Royal Society of Chemistryrotation was measured using a Kruss Optronic GmbH P8000
polarimeter with a 0.5 mL cell (concentration c given as g/100
mL). The purity of nal tested compounds was $95% as
determined by 1H-NMR, and HPLC.
Synthesis of diethyl 2,5-dihydroxy-1,4-dithiane-2,5-
dicarboxylate 3
To a stirred solution of ethyl 3-bromopyruvate (14 g, 0.071 mol) in
MeOH (125 mL) cooled at 10 C, was added a cooled (0 C)
suspension of NaHS (11 g, 0.20mol) inMeOH (125mL) at 2mL per
minute. A white solid is formed during the addition, and cooling
with stirring was continued for 1 h. The solid was collected, washed
with Et2O (50 mL) and dried to give 3 as white solid (7.8 g, yield
73%). 1H-NMR (400 MHz, DMSO-d6) d 6.98 (s, 2H), 4.18 (q, J ¼
7.1 Hz, 4H), 3.65 (d, J¼ 14.1 Hz, 2H), 2.87 (d, J¼ 14.1 Hz, 2H), 1.23
(t, J ¼ 7.1 Hz, 6H) according to reported values in literature.34
Synthesis of (2S,4R)-2-(ethoxycarbonyl)-2-(mercaptomethyl)
thiazolidine-4-carboxylic acid (L-anti-1a)
To a stirred suspension of L-cysteine (L-2a) (1 g, 8.3 mmol) in
MeOH (20 mL) was added under N2, dithiane 3 (1.4 g, 2.76
mmol), LiCl (35mg, 0.82 mmol) and heated at reux for 2 h. The
reaction mixture was concentrated under reduced pressure. The
residue was poured into H2O (60 mL), the pH was adjusted to 3
with HCl 1 M, and extracted with AcOEt (3  60 mL). The
combined organic layers were dried (Na2SO4), ltered and
concentrated. A crude reaction was obtained as a diastereo-
meric mixture of L-anti/syn-1a 70 : 30. The crude was puried by
SiO2 using nHex : AcOEt : AcOH (70 : 29 : 1) to afford L-anti-1a
as white solid (0.32 g, yield 40%), mp 99.1–101 C. 1H-NMR (400
MHz, CDCl3) d 4.36–4.29 (m, 2H), 4.11 (dd, J ¼ 9.0, 6.2 Hz, 1H),
3.43 (dd, J ¼ 10.7, 6.2 Hz, 1H), 3.06–3.01 (m, 1H), 3.03 (d, J ¼
8.4 Hz, 2H), 1.97 (t, J ¼ 8.4 Hz, 1H), 1.34 (t, J ¼ 7.1 Hz, 3H), 0.86
(br, NH). 13C-NMR (100 MHz, CDCl3) d 174.1, 171.0, 79.3, 65.0,
62.9, 39.2, 33.6, 14.0. [a]21D ¼ 94.12 (c 2.6, AcOEt).
Synthesis of (2R,4S)-2-(ethoxycarbonyl)-2-(mercaptomethyl)
thiazolidine-4-carboxylic acid (D-anti-1a)
Prepared in analogous route as described for L-anti-1a, starting
from D-cysteine D-2a and dithiane 3. The crude was puried by
SiO2 using nHex : AcOEt : AcOH (70 : 29 : 1) to afford D-anti-1a
as a white solid, yield 48%. The spectroscopic properties were
identical to those obtained for L-anti-1a. HRMS calculated for
C8H13NO4S2 [MNa]
+ 274.0184, found 274.0178.
Synthesis of (2S/R,4R)-2-(ethoxycarbonyl)-2-(mercaptomethyl)-
5,5-dimethylthiazolidine-4-carboxylic acid (L-anti/syn-1b)
Prepared in analogous route as described for L-anti-1a,
starting from L-penicillamine L-2b and dithiane 3. A crude
reaction was obtained as a diastereomeric mixture (L-anti/syn-
1b 60 : 40). The crude was puried by SiO2 using
nHex : AcOEt : AcOH (70 : 29 : 1) to afford L-anti-1b 46%
yield, and L-syn-1b 41% yield.
(2S,4R)-2-(Ethoxycarbonyl)-2-(mercaptomethyl)-5,5-dimethyl
thiazolidine-4-carboxylic acid (L-anti-1b). Colourless oil, yieldChem. Sci.































































































View Article Online46%. 1H-NMR (400 MHz, CDCl3) d 4.37–4.26 (m, 2H), 3.84 (s,
1H), 3.03–3.00 (m, 1H), 2.96–2.90 (m, 1H), 2.00 (s, 1H, br), 1.62
(s, 2H), 1.33 (t, J ¼ 7.1 Hz, 3H), 1.30 (s, 3H). 13C-NMR (100 MHz,
CDCl3) d 173.5, 171.3, 76.1, 72.5, 62.6, 60.7, 34.1, 26.5, 26.1, 14.0.
HRMS calculated for C10H17NO4S2 [MNa]
+ 302.0491, found
302.0490; [a]21D ¼ 49.1 (c 1.9, AcOEt).
(2R,4R)-2-(Ethoxycarbonyl)-2-(mercaptomethyl)-5,5-dimethyl
thiazolidine-4-carboxylic acid (L-syn-1b). Colourless oil, yield
41%. 1H-NMR (400 MHz, CDCl3) d 4.31–4.20 (m, 3H), 3.25 (d, J ¼
14.4 Hz, 1H), 3.11 (d, J ¼ 14.4 Hz, 1H), 1.64 (s, 3H), 1.40 (s, 3H),
1.31 (t, J¼ 7.1 Hz, 3H). 13C-NMR (100MHz, CDCl3) d 173.1, 171.3,
76.7, 73.3, 62.1, 59.4, 32.4, 28.1, 27.2, 13.9. C10H17NO4S2 [MNa]
+
302.0491, found 302.0490. [a]21D ¼ 124.7 (c 1.44, CH3OH).Synthesis of (2S/R,4S)-2-(ethoxycarbonyl)-2-(mercaptomethyl)-
5,5-dimethylthiazolidine-4-carboxylic acid (D-anti/syn-1b)
Prepared in analogous route as described for L-anti-1a, starting
from D-penicillamine D-2b, and dithiane 3. The residue was
puried by SiO2 using nHex : AcOEt : AcOH (60 : 40 : 0.5) to
afford D-anti-1b 44% yield, and D-syn-1b 40% yield.
(2R,4S)-2-(Ethoxycarbonyl)-2-(mercaptomethyl)-5,5-dimethyl
thiazolidine-4-carboxylic acid (D-anti-1b). Colourless oil, yield
44%; the spectroscopic properties were identical to those ob-
tained for L-anti-1b, [a]21D ¼ +42.5 (c 1.6, AcOEt). HRMS calcu-
lated for C10H17NO4S2, [MNa]
+ 302.0491, found 302.0521.
(2S,4S)-2-(Ethoxycarbonyl)-2-(mercaptomethyl)-5,5-dimethyl
thiazolidine-4-carboxylic acid (D-syn-1b). Colourless oil, yield
40%; the spectroscopic properties were identical to those ob-
tained for L-syn-1b. [a]21D ¼ +129.5 (c 1.7, CH3OH). HRMS
calculated for C10H16NO4S2 [M2Na]
+ 324.0316, found 324.0314.Author contributions
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23 M. M. González, M. Kosmopoulou, M. F. Mojica, V. Castillo,
P. Hinchliffe, I. Pettinati, J. Brem, C. J. Schoeld, G. Mahler,
R. A. Bonomo, L. I. Llarrull, J. Spencer and A. J. Vila, ACS
Infect. Dis., 2016, 1, 544–554.
24 M. F. Mojica, S. G. Mahler, C. R. Bethel, M. A. Taracila,
M. Kosmopoulou, K. M. Papp-Wallace, L. I. Llarrull,
B. M. Wilson, S. H. Marshall, C. J. Wallace, M. V. Villegas,
M. E. Harris, A. J. Vila, J. Spencer and R. A. Bonomo,
Biochemistry, 2015, 54, 3183–3196.
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